Product
rucaparib
Aliases
Rucaparib
Name
Rubraca
FDA Approved
Yes
1 clinical trial
2 organizations
1 drug
1 indication
1 document
Indication
Prostate CancerDrug
rucaparibClinical trial
A Phase 2 Study of Nivolumab in Combination With Either Rucaparib, Docetaxel, or Enzalutamide in Men With Castration-resistant Metastatic Prostate CancerStatus: Active (not recruiting), Estimated PCD: 2021-01-13
Document
DailyMed Label: RubracaOrganization
pharmaand GmbHOrganization
Clovis Oncology, Inc.